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1 Drug description 
Generic/Brand name:  
Everolimus (RAD-001)/Afinitor® 
 
Developer/Company:  
 
Novartis 
 
 
Description:   
Everolimus is an oral inhibitor of the mammalian target of rapamycin 
(mTOR), a serine-threonin kinase. Mechanisms of action include the inhibi-
tion of the mTor kinase whose pleiotropic activity is up-regulated in many 
human cancers, the reduction of vascular endothelian growth factor (VEGF) 
expression and the inhibition of hypoxia inducible factor (HIF-1) expres-
sion. Ultimately, cell proliferation, angiogenesis and glucose up-take are 
slowed down and therefore, further growth of cancer cells is reduced or 
stopped [1, 2].  
There are 5 mg and 10 mg tablets for oral administration. The usual dose is 
10 mg once daily, but dose reduction to 5 mg might become necessary for the 
management of adverse effects. Maximum daily dose should not exceed 20 
mg and treatment should be continued as long as clinical benefits can be ob-
served and as long as toxicity remains acceptable [1].   
2 Indication 
Everolimus (Afinitor®) is indicated for the treatment of patients with metas-
tatic or advanced renal cell carcinoma after failure of treatment with sunit-
inib or sorafenib.  
3 Burden of disease 
Renal cell cancer (RCC), with about 90% the most common type of kidney 
cancer [3], is newly diagnosed in about 40,000 patients each year in Europe 
and can be held accountable for an estimated annual 20,000 deaths [4].  
Associated risk factors are smoking and obesity, as well as genetic abnor-
malities [3]. Median age of RCC diagnosis is at 65 years [3] with more men 
than women  being affected [5]. 
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Risk stratification is important for choosing the most appropriate therapy. 
The most common model to predict short survival is the Memorial Sloan-
Kettering Cancer Centre or Motzer criteria (MSKCC) which are based on 
risk-factors or predictors, such as high blood levels of lactate dehydrogenase 
and calcium, anaemia, time of less than a year from diagnosis to the need for 
systemic treatment and low performance status (Karnofsky performance 
status <80%). Depending on the number of risk factors three groups can be 
stratified: a good, intermediate or poor risk-group [3]. 
Staging of renal cancer depends on the tumour grade, local extent of the tu-
mour, presence of metastases in the regional lymph nodes or metastatic dis-
ease.  In contrast to localized tumours with a high probability of cure (stage 
I/II), more advanced forms with either metastases in the regional lymph 
nodes (stage III) or with distant metastases (stage IV) of kidney cancer are 
linked to poor outcomes. Estimated average 5-year survival rate for patients 
ranges from 23% (stage IV) to 64% (stage III) [3].  
Due to the often asymptomatic course of the disease, about 25% to 30% of 
patients are diagnosed when the tumour has already metastasised [6, 7]. 
Applying this estimate to the Austrian context  (with an overall incidence of 
1209 renal cancer cases in 2006 [8])  - results in about 300 patients per year. 
20% to 30% of patients with previously localized tumours relapse one to two 
years after surgery [3]. 
4 Current treatment  
For stage III RCC, primary treatment consists of radical nephrectomy with 
or without lymph node dissection. For stage IV cancers, surgery is also an 
option and might include nephrectomy and/or metastasectomy. 
In addition to best supportive care, options for first- and second-line therapy 
for patients who relapse or with stage IV RCC and medically or surgically 
unresectable cancer are 
 cytokines (interferon-α, high-dose interleukin-2) 
 monoclonal anti-VEGF antibodies (bevacizumab) 
 multi kinase inhibitors with activity  including the downstream sig-
nalling of the vascular endothelian growth factor receptor (VEGF-
R) (sorafenib, sunitinib) 
 mTor inhibitors (temsirolimus) [3]. 
Until recently, cytokines were the only available systemic treatment options 
for metastatic RCC but were limited to patients with a good risk profile and 
were  accompanied by  substantial  treatment  related morbidity  [6,  9].    This 
has changed with the availability of other treatments such as targeted thera‐
pies using multi kinase or mTOR inhibitors.  
The EMEA approved sunitinib, sorafenib for patients who have failed prior 
interferon-α or interleukin-2 therapy [10], bevacizumab in combination with 
interferon‐α  and finally, temsirolimus as first-line treatment for patients 
with advanced RCC and poor prognosis (according to MSKCC) [10]. 
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5 Current regulatory status 
Orphan drug designation was granted by European Medicines Agency 
(EMEA) in June 2007. In May 2009, the Committee for Medicinal Products 
for Human Use adopted a positive opinion to recommend marketing au-
thorisation for everolimus for 
 patients with advanced renal cell carcinoma whose disease has pro-
gressed on or after treatment with VEGF-targeted therapy [2].  
The final EU market authorization was granted in August 2009 [11, 12].  
The United States Food and Drug Administration (FDA) granted approval 
for everolimus for  
 the treatment of patients with advanced renal cell carcinoma after 
failure of treatment with sunitinib or sorafenib in March 2009 [1].  
Everolimus (Certican®) is also approved for the prevention of transplant re-
jection [13]. 
6 Evidence 
Two studies evaluating everolimus were identified. One phase III trial allo-
cated RCC patients, in whom previous therapies - mainly sunitinib or soraf-
enib - have failed, to either everolimus or placebo therapy. Improved pro-
gression free survival was observed for the active treatment group (4.0 
months) in comparison to the control group (1.9 months). No difference was 
found for overall survival or quality of life.  
The single arm phase II trial included 37 patients with one previous therapy 
and metastatic RCC for the analysis. Median overall survival was 22.1 
months, and median progression-free survival was 11.2 months. 
The majority of side-effects were of grade 1 or grade 2 in both studies.  
6.1 Efficacy and safety - phase III studies 
 
Reference NCT00410124, published [14] 
Sponsor Novartis Oncology 
Country Australia, Canada, Europe, Japan, USA 
Design Multi-centre, double-blind, randomised phase III trial, crossover to ever-
olimus if disease progression was observed in placebo group 
Participants characteristics 410 pts1 (I 272 vs C 138), median age: I 61 years (range: 27 – 85 years) vs C 
60 years (range: 29 – 79 years) 
 
1 pts= Patients, 
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Treatments 
 
 
Intervention: oral 10 mg everolimus/day in a 28 day cycle and best sup-
portive care 
Control: placebo and best supportive care 
Treatment duration: until disease progression, unacceptable toxicity,
death, discontinuation for any other reason.  
In-/exclusion criteria Inclusion: adults with metastatic renal cell carcinoma with clear-cell 
component, progression on or within 6 months of stopping treatment 
with sunitib and/or sorafenib, or previous therapy with bevacizumab, IL-
2, IF-α; Karnofsky-performance status score ≥ 70% 
Exclusion: previous treatment with mTOR inhibitor, untreated CNS me-
tastases, uncontrolled medical conditions (diabetes, unstable angina pec-
toris, symptomatic congestive heart failure, recent myocardial infarc-
tion) 
Follow-up Scheduled recruitment period of 16 months and an additional follow-up 
of 5 months, but trial was terminated after second interim analysis be-
cause  criteria for positive study were met 
Outcomes Primary: progression-free survival 
Secondary: safety, objective tumour response rate, overall survival, dis-
ease-related symptoms, quality-of-life 
Key results Median progression free-survival (blinded independent central review): I 
4.0 months (95% CI2: 3.7, 5.5) vs  C 1.9 months (95% CI:1.8, 1.9), HR 2= 
0.30 (95% CI: 0.22, 0.40; p< 0.0001) 
Objective tumour response: I 3 pts (1%) vs C 0 pts (0%) 
Overall survival: HR = 0.83 (95% CI: 0.50, 1.37; p = 0.23) 
Global health status/quality-of-life score: HR= 1.02 (95% CI: 0.70, 1.50) 
Adverse effects All grades:  stomatitis (all grades): I 40% vs C 11%, rash: I 25% vs C 4%, 
fatigue: I 20% vs C 16%, anaemia: I 91% vs C 76%, hypercholesterinae-
mia: I 76% vs C 32%, hyperglycaemia: I 50% vs C 23%,  
Grade 3:  anaemia: I 9% vs C 5%; hyperglycaemia I 12% vs C 1%, lym-
phopenia I 14% vs C 5%, pneumonitis I 3% vs C 0% 
Grade 4: more often in everolimus group, always ≤1% 
Commentary Everolimus was associated with a reduction in the risk of progression or 
death compared with placebo in patients with metastatic renal cell carci-
noma whose disease had progressed after treatment with VEGF-targeted 
therapies. Clinical resistance to VEGF inhibitors does not imply resistance 
to mTOR inhibitors.  
 
2 CI = Confidence Interval 
3 HR = Hazard Ratio 
This randomised phase III trial included 410 patients, mainly with favour-
able or intermediate risk features according to the MSKCC. 15% of patients 
in the intervention and placebo group were classified as being at poor risk.  
Improved progression-free survival was found for the everolimus group and 
was similar across all risk subgroups. Yet, no significant difference of overall 
survival was demonstrated between intervention and placebo group. Accord-
ing to the authors, this might be due to the fact that out of 98 patients who 
progressed in the placebo group, 79 were allowed to crossover to the ever-
olimus group.  
Adverse effects were more common in the everolimus group but were mostly 
of grade 1 or grade 2. Due to drug related toxicity, treatment discontinua-
tion occurred in 28 patients (10%) in the intervention group in comparison 
to five patients (4%) in the placebo group. 5% in the everolimus group died 
within 28 days of their last dose (one might have been attributable to treat-
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ment) and 4% in the control group.  
The trial was stopped early as the criteria for a positive study (≥60% of tar-
geted 290 progression free events were observed) were met after the second 
interim analysis and the remaining patients in the placebo group were al-
lowed to cross-over to the active treatment arm [15]. 
6.2 Efficacy and safety - further studies 
Another company sponsored, single-armed phase II study enrolled 41 pa-
tients with predominantly clear cell RCC and progressive metastatic disease 
with ≤1prior therapy [16]. 10 mg everolimus were administered every day for 
8 weeks or until disease progression. Patients were mostly at MSKCC inter-
mediate risk (58.5%) or at good risk (36.6%).  Additionally, 17% of the study 
population had not been treated previously with any systemic therapy. 
Based on the findings of 37 patients, median progression-free survival was 
11.2 (95% CI: 1.7, 36.2) months; median overall survival was 22.1 (95% CI: 
1.4, 36.4) months. Stable disease for ≥3 months was observed in 27 patients 
and for ≥ 6 months in 21 patients. 
Most common side effects were of grade 1 or 2, including anorexia (38%), 
nausea (38%), diarrhoea (31%), stomatitis (31%) and rash (26). Hematologic 
adverse effects of grade 3 were thrombocytopenia (7.7%), hyperglycaemia 
(7.7%) and hypercholesterolemia (5.1%).  
Additionally, one previous horizon scanning report was identified [7]. 
7 Estimated costs 
The manufacturer’s price for one package Afinitor®  10  mg  containing  30 
tablets is € 3,600, yielding € 120 for one tablet daily [17]. These costs occur 
as long as clinical benefits can be observed and as long as toxicity remains 
acceptable. In the above mentioned phase III trial, median duration of treat-
ment was 95 days for the everolimus group. Assuming the same treatment 
duration, costs additional to expenses for previous therapies would be 
€ 11,400. But because the preferred sequence of the new therapies in RCC is 
unclear, some of these costs will be additive and others alternative to exist-
ing ones. 
8 Ongoing research 
One ongoing phase III trial was found on Clinical trials.com: 
NCT00410124: The trial on which the presented results are based is still on-
going to assess the secondary endpoint of overall survival [18].  
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However, plenty phase I and phase II trials were identified. Research topics 
include everolimus as first-line therapy for patients with metastatic kidney 
cancer, in combination with other drugs, such as bevacizumab or sorafenib, 
or for a broad range of other cancer types [19].  
9 Commentary - English 
The two studies presented in this report showed improved progression-free 
survival in patients with metastatic RCC treated with everolimus as second 
line therapy. Since no other standard treatment exists for patients, in whom 
previous targeted therapies have failed, everolimus provides a treatment op-
tion for those patients [15, 18]. Consequently, the drug was approved by the 
EMEA and the FDA for the treatment of patients with advanced/metastatic 
RCC after treatment failure of sunitinib and/or sorafenib.  
Progression-free survival, the primary outcome of the phase III trial, was 4.0 
months (95% CI: 3.7, 5.5) in the everolimus group and 1.9 months (95% CI: 
1.8, 1.9) in the placebo group (HR = 0.30), leading to a modest difference of 
2.1 months. As confirmed objective tumour response was seen in only 1% of 
the everolimus group and in 0% of the placebo group, the advantage in pro-
gression-free survival is mainly the result of disease stabilisation.  
No improvements for the intervention group were observed either with re-
gards to quality-of-life scores or to overall survival. The most frequent ob-
served adverse effects were of grade 1 or grade 2. 
Unequivocally, everolimus is “the first and only agent with established clini-
cal benefit for the treatment of patients with RCC after tyrosine kinase in-
hibitor therapy [15]”. Nevertheless, improvements in overall survival for 
everolimus are still missing. The authors argue that results might have been 
confounded by reasons that patients were allowed to cross-over to the active 
treatment arm for ethical reasons. Therefore, it remains questionable if a 
placebo controlled trial was an appropriate study design. Temsirolimus, like 
everolimus an mTOR inhibitor, has demonstrated improved overall survival 
in comparison to another active agent (IF-α) for, admittedly, previously un-
treated RCC patients [4, 9]. Hence, the direct head-to-head comparison of 
both mTOR inhibitors would have been a better way to determine the real 
benefit of everolimus.   
Until recently, treatment options for advanced/metastatic RCC were quite 
limited.   This  has  changed with  the  availability  of  a  number  of  new drugs 
such  as  sunitinib, sorafenib or temsirolimus. Hence, the remaining chal-
lenge is the identification of the most effective drugs with the least side ef-
fects for the treatment of RCC, as well as the determination of the best se-
quence or combination of these new therapies. Everolimus might offer ad-
vantages over other drugs in terms of oral application and acceptable side-
effects, but its value for the treatment of RCC has not been established yet.   
Because the principle of mTOR inhibition applies to a broad range of ma-
lignancies (multiple clinical trials ongoing) there is a relevant potential for 
off-label use of Everolimus. 
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10 Commentary - German 
Eine Phase III Studie zeigte bei PatientInnen mit metastasiertem Nieren-
zellkarzinom (RCC), die mit Everolimus als Zweitlinien-Therapie behandelt 
worden waren, längeres progressionsfreies Überleben (PFS) im Vergleich zu 
Placebo. Da bisher keine Standardtherapie für mit „Targeted therapies“ vor-
behandelten PatientInnen existiert, stellt Everolimus erstmals eine Thera-
pieoption für diese Personen dar [15, 18]. Daher wurde Everolimus sowohl 
von der EMEA als auch von der FDA zur Behandlung von metastasier-
tem/fortgeschrittenem RCC nach Therapieversagen von Sunitinib und/oder 
Sorafenib zugelassen.  
PFS, der primäre Endpunkt der Phase III Studie, war 4.0 Monate (95% CI: 
3.7, 5,5) in der Everolimusgruppe und 1.9 Monate (95% CI: 1.8, 1.9) in der 
Placebogruppe (HR= 0.30), wodurch sich eine Differenz von 2.1 Monaten 
ergab. Da eine bestätigte objektive Tumorresponse in 1% der Everoli-
musgruppe und in 0% der Placebogruppe beobachtet worden war, ist das 
verlängerte PFS damit hauptsächlich auf eine Stabilisierung der Erkran-
kung zurückzuführen.  
Keine Unterschiede wurden für den aktiven Behandlungsarm in Bezug auf 
Lebensqualität oder Gesamtüberleben gefunden. Die am häufigsten beo-
bachteten unerwünschten Nebenwirkungen waren Grad 1 oder Grad 2. 
Zweifellos ist „Everolimus das erste und einzige Medikament mit bewiese-
nem klinischem Nutzen zur Behandlung von PatientInnen mit RCC nach 
einer Therapie mit Tyrosin-Kinase-Inhibitoren“ [15], trotz allem ist der 
Nachweis eines verlängerten Gesamtüberlebens nach wie vor ausständig. 
Die Autoren der Phase III Studie argumentieren, dass dies möglicherweise 
durch das Cross-over Design der Studie bedingt ist, weil aufgrund ethischer 
Überlegungen PatientInnen der Placebogruppe zur aktiven Therapie über-
wechseln durften. Fragwürdig ist daher, ob eine Placebo-kontrollierte Studie 
tatsächlich das beste Studiendesign war. Für  Temsirolimus, wie Everolimus 
auch ein mTOR Inhibitor, zeigte eine Studie ein verlängertes Gesamtüber-
leben im Vergleich zu einem anderen, aktiven Medikament (IF-α) - aller-
dings für noch unbehandelte PatientInnen [4, 9].  Der direkte Vergleich der 
beiden mTOR Inhibitoren wäre daher möglicherweise ein besserer Weg ge-
wesen, um den tatsächlichen Nutzen von Everolimus zu bestimmen. 
Bis vor kurzem waren die Behandlungsmöglichkeiten für metastasier-
tes/fortgeschrittenes RCC eingeschränkt. Durch die Verfügbarkeit neuer 
Medikamente wie Sorafenib, Sunitinib oder Temsirolimus stehen nun aber 
zahlreiche Therapien zur Verfügung. Die verbleibende Herausforderung ist 
nun, sowohl die effektivsten und nebenwirkungsärmsten Medikamente zu 
identifizieren, als auch die beste Therapieabfolge zu bestimmen. Everolimus 
bietet aufgrund seiner einfachen Verabreichungsform und der akzeptablen 
Nebenwirkungen zweifellos einige Vorteile gegenüber anderen Therapien, 
allerdings ist der endgültige  Stellenwert von Everolimus in der Behandlung 
des RCC noch nicht bewiesen.  
Da das Prinzip der mTOR Inhibition bei sehr vielen Malignomen potentiell 
wirksam sein könnte (viele klinische Studien anhängig), besteht ein relevan-
tes Potential des off-label Gebrauchs dieser Substanz. 
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